Darbepoetin for the anaemia of chronic kidney disease-Reference-Cited by-同舟云学术

Darbepoetin for the anaemia of chronic kidney disease

Published:2014-03-31 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Palmer Suetonia C¹,Saglimbene Valeria²,Craig Jonathan C³,Navaneethan Sankar D⁴,Strippoli Giovanni FM³⁵⁶⁷⁸

Affiliation:

1. University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140

2. Mario Negri Sud Consortium; Clinical Pharmacology and Epidemiology; Via Nazionale 8/A Santa Maria Imbaro Chieti Italy 66030

3. The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006

4. Glickman Urological and Kidney Institute, Cleveland Clinic; Department of Nephrology and Hypertension; Cleveland OH USA 44195

5. The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145

6. University of Bari; Department of Emergency and Organ Transplantation; Bari Italy 70100

7. Mario Negri Sud Consortium; Department of Clinical Pharmacology and Epidemiology; Santa Maria Imbaro Italy

8. Diaverum; Medical-Scientific Office; Lund Sweden. Amedeo Avogadro University of Eastern Piedmont; Division of Nephrology and Transplantation, Department of Translational Medicine; Novara Italy 28100

Publisher

Wiley

Subject

Pharmacology (medical)

Reference173 articles.

1. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa;Aarup;Nephrology Dialysis Transplantation,2006

2. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of Aranesp® (darbepoetin alfa) [abstract no: PUB278];Aarup;Journal of the American Society of Nephrology,2004

3. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study;Akizawa;Therapeutic Apheresis & Dialysis,2011

4. Target level for hemoglobin correction by darbepoetin alfa (KRN321) for patients with chronic kidney disease (CKD) not on dialysis in randomized controlled study; from the viewpoint of the efficacy [abstract no: SU-PO804];Akizawa;Journal of the American Society of Nephrology,2007

5. High target hemoglobin with erythropoiesis stimulating agent (ESA) in chronic kidney disease (CKD) slows the occurrence rate of events related to decline of renal function [abstract no: SA-FC341];Tsubakihara;Journal of the American Society of Nephrology,2009

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of darbepoetin therapy on platelet count and function in healthy cats and cats with surgically induced chronic kidney disease;American Journal of Veterinary Research;2024-06-17

2. Advancing Anemia Management in Chronic Kidney Disease: Assessing the Superiority of Darbepoetin Alfa Over Erythropoietin Alpha;Cureus;2024-01-03

3. Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022;Clinical and Experimental Nephrology;2023-10-25

4. Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial;Clinical and Experimental Nephrology;2023-06-08

5. Hemoglobin modulation affects physiology and patient reported outcomes in anemic and non-anemic subjects: An umbrella review;Frontiers in Physiology;2023-02-15